Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer : ARTemis Trial
- Submitting institution
-
The University of Warwick
- Unit of assessment
- 2 - Public Health, Health Services and Primary Care
- Output identifier
- 10421
- Type
- D - Journal article
- DOI
-
10.1093/annonc/mdx173
- Title of journal
- Annals of Oncology
- Article number
- -
- First page
- 1817
- Volume
- 28
- Issue
- 8
- ISSN
- 0923-7534
- Open access status
- Compliant
- Month of publication
- August
- Year of publication
- 2017
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
19
- Research group(s)
-
-
- Citation count
- 15
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- The author made a substantial contribution to the conception and design of the study, and to the organisation of the conduct of the study and to the carrying out of the study and the analysis and interpretation of the study data. The author helped draft the output and helped critique the output for important intellectual content.
- Non-English
- No
- English abstract
- -